A randomized, double-blind, placebo-controlled, phase II, dose finding, multicenter study to explore the safety, tolerability, efficacy, and pharmacokinetics of fosalvudine tidoxil capsules in antiretroviral naive patients infected with HIV-1.

Trial Profile

A randomized, double-blind, placebo-controlled, phase II, dose finding, multicenter study to explore the safety, tolerability, efficacy, and pharmacokinetics of fosalvudine tidoxil capsules in antiretroviral naive patients infected with HIV-1.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Fosalvudine tidoxil (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Heidelberg Pharma; Heidelberg Pharma Research
  • Most Recent Events

    • 09 Oct 2017 According to the WILEX AG media release, Heidelberg Pharma changed its name to Heidelberg Pharma Research.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top